Epigenomics, Wuhan Kindstar Ink Deal for Lung Cancer Assay in China | GenomeWeb

NEW YORK (GenomeWeb News) – Epigenomics and Wuhan Kindstar Clinical Diagnostics today announced a licensing and supply deal for the Epi proLung tissue assay for the Chinese market.

The terms of the deal call for Kindstar to commercialize Epigenomics' assay, while the Berlin-based company will manufacture and supply it. Epigenomics also will provide support "with respect to medical and regulatory considerations."

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.